Exercise Training and Metabolic Syndrome
Primary Purpose
Metabolic Syndrome
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Aerobic interval training
Sponsored by
About this trial
This is an interventional treatment trial for Metabolic Syndrome focused on measuring aerobic interval training, biomarkers
Eligibility Criteria
Inclusion Criteria:
- Having metabolic syndrome according to international diabetes foundations definition (IDF).
- Age between 35 - 60 years and untrained subjects.
Exclusion Criteria:
- Musculotendinous or osteoarticular injuries in the lower limbs and/or spine
- Chronic pulmonary diseases
- Neurological disorders
- Kidney failure
- High-risk cardiovascular diseases (Unstable angina pectoris, Uncompensated heart failure, complex ventricular arrhythmias or myocardial infarction during the last month).
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
intervention
Control group
Arm Description
Aerobic interval training
The participants performed only initial evaluation and at the end of the study
Outcomes
Primary Outcome Measures
Pro-inflammatory marker
Serum levels of C-reactive protein
Secondary Outcome Measures
Quality of life
The Medical Outcomes Study-Short Form 36 (SF-36)
A set of clinical biomarkers
Serum levels lof Homocysteine; Creatinine, Creatine kinase (ck); creatine kinase MB (ck-mb); Troponin t; aspartate aminotransferase; alanine aminotransferase; and complete blood count.
Full Information
NCT ID
NCT03036332
First Posted
January 26, 2017
Last Updated
January 27, 2017
Sponsor
Universidade Estadual Paulista Júlio de Mesquita Filho
1. Study Identification
Unique Protocol Identification Number
NCT03036332
Brief Title
Exercise Training and Metabolic Syndrome
Official Title
Effects of Aerobic Interval Training on Clinical Biomarkers and Quality of Life in Metabolic Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
June 1, 2015 (Actual)
Primary Completion Date
December 10, 2016 (Actual)
Study Completion Date
December 10, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universidade Estadual Paulista Júlio de Mesquita Filho
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The present study aimed to determine the effects of 16 weeks of aerobic interval training on quality of life and a set of clinical biomarkers.
Detailed Description
Besides the traditional metabolic syndrome risk factors (dyslipidemia, raised blood pressure, central obesity and dysglycemia) subclinical disorders related to chronic inflammation and cell damage have been reported on metabolic syndrome. Therefore, regarding the systemic feature of metabolic syndrome, we investigated an new approach of aerobic interval training on several clinical biomarkers widely used. Such training used differs from current aerobic protocols in order to attenuate metabolic and musculoskeletal overload on untrained and unhealthy subjects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome
Keywords
aerobic interval training, biomarkers
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Non-Randomized
Enrollment
53 (Actual)
8. Arms, Groups, and Interventions
Arm Title
intervention
Arm Type
Experimental
Arm Description
Aerobic interval training
Arm Title
Control group
Arm Type
No Intervention
Arm Description
The participants performed only initial evaluation and at the end of the study
Intervention Type
Behavioral
Intervention Name(s)
Aerobic interval training
Intervention Description
Carried out 3 times per week for 16 weeks
Primary Outcome Measure Information:
Title
Pro-inflammatory marker
Description
Serum levels of C-reactive protein
Time Frame
16 weeks
Secondary Outcome Measure Information:
Title
Quality of life
Description
The Medical Outcomes Study-Short Form 36 (SF-36)
Time Frame
16 weeks
Title
A set of clinical biomarkers
Description
Serum levels lof Homocysteine; Creatinine, Creatine kinase (ck); creatine kinase MB (ck-mb); Troponin t; aspartate aminotransferase; alanine aminotransferase; and complete blood count.
Time Frame
16 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Having metabolic syndrome according to international diabetes foundations definition (IDF).
Age between 35 - 60 years and untrained subjects.
Exclusion Criteria:
Musculotendinous or osteoarticular injuries in the lower limbs and/or spine
Chronic pulmonary diseases
Neurological disorders
Kidney failure
High-risk cardiovascular diseases (Unstable angina pectoris, Uncompensated heart failure, complex ventricular arrhythmias or myocardial infarction during the last month).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rodolfo AT Miranda, Me
Organizational Affiliation
Universidade Estadual Paulista Júlio de Mesquita
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Exercise Training and Metabolic Syndrome
We'll reach out to this number within 24 hrs